News

GMO acreage reaches new high
Enlarge image

BusinessEUSpainGermanyPoland

GMO acreage reaches new high

21.02.2013 - Global acreage of biotech crops have increased by 6% last year. Europe contributes only 0.075%.

Brussels/Manila - Genetically modified (GM) soybeans, maize, cotton and rapeseed were planted on 170.3 million hectares last year, according to figures from the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). However, the adoption of biotech crops has become slower. After double digit growth rates three years ago, this year the cultivation area increased only by 6 percent or 10.3 million hectares compared to 2011. 

However, Europe remains a minor player in the growing market for GMOs due to public hostility to GMOs. The EU countries grew 129,071 hectares of Bt maize, about 14,000 hectares more than in 2011. Spain remained the leading EU country for GMO acreage with 116,306 hectares in 2012. Poland discontinued the planting of biotech maize.  The US (69.5m ha, +0.7%), Brazil (36.6m ha, +20,8%), Argentina (23.9m ha, +0,8%), Canada (11.6m ha, +11,5), and India (10.6m ha, +1,8%) were the leading GMO producers. Global Adoption of GM soybeans (+8%), cotton (+7%), maize (+4%), and rapeseed (+5%) increased as compared to 2011.  

"There is one principal and overwhelming reason that underpins the trust and confidence of farmers in biotechnology: biotech crops deliver substantial, and sustainable, socio-economic and environmental benefits," stressed ISAAA chief Clive James. In fact, German BASF and Monsanto both filed for US approval of the first drought-tolerant crop last year. However, the US Department of Agriculture recently delayed the approval of new herbicide-tolerant GMOs because weeds are becoming more and more resistant to the herbicide Glyphosate, which is marketed together with Glyphosate-tolerant GMOs since 1996.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/gmo-acreage-reaches-new-high.html

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR429.6%
  • GALAPAGOS (B)54.03 EUR332.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • EVOCUTIS (UK)0.19 GBP-81.9%
  • BIOTEST (D)19.92 EUR-77.2%

No liability assumed, Date: 31.08.2015